Research Analysts Issue Forecasts for BioCryst Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Research analysts at HC Wainwright lifted their Q2 2024 earnings estimates for shares of BioCryst Pharmaceuticals in a research note issued to investors on Tuesday, May 7th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of ($0.14) for the quarter, up from their prior forecast of ($0.16). HC Wainwright has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals' Q3 2024 earnings at ($0.10) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.51) EPS, FY2025 earnings at ($0.08) EPS and FY2026 earnings at $0.43 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The firm had revenue of $92.80 million during the quarter, compared to analysts' expectations of $85.62 million. During the same quarter in the previous year, the firm posted ($0.28) EPS. The firm's revenue for the quarter was up 34.9% on a year-over-year basis.

Other analysts also recently issued reports about the company. JMP Securities lifted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "market outperform" rating in a report on Tuesday. Needham & Company LLC reissued a "buy" rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $14.00.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX traded up $0.24 on Thursday, reaching $5.34. 3,336,303 shares of the stock traded hands, compared to its average volume of 3,399,351. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $8.96. The company has a fifty day moving average price of $4.89 and a 200-day moving average price of $5.45. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -4.83 and a beta of 1.96.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BCRX. Braidwell LP boosted its stake in BioCryst Pharmaceuticals by 92.1% in the third quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company's stock valued at $37,970,000 after acquiring an additional 2,571,100 shares in the last quarter. Vanguard Group Inc. increased its position in BioCryst Pharmaceuticals by 15.4% during the 4th quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company's stock valued at $106,405,000 after buying an additional 2,371,401 shares in the last quarter. Norges Bank purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at about $13,278,000. Deerfield Management Company L.P. Series C boosted its holdings in BioCryst Pharmaceuticals by 148.6% in the third quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company's stock worth $23,265,000 after acquiring an additional 1,964,000 shares in the last quarter. Finally, Avoro Capital Advisors LLC grew its stake in shares of BioCryst Pharmaceuticals by 13.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company's stock worth $78,170,000 after acquiring an additional 1,500,000 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.